Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Rosen Law Firm Reminds Star Scientific Shareholders of Important May 24, 2013 Deadline in Class Action Filed by the Firm --



Rosen Law Firm Reminds Star Scientific Shareholders of Important May 24, 2013
Deadline in Class Action Filed by the Firm -- STSI

NEW YORK, May 4, 2013 (GLOBE NEWSWIRE) -- The Rosen Law Firm reminds investors
of the important May 24, 2013 lead plaintiff deadline in the class action
lawsuit filed by the firm on behalf of investors who purchased common stock of
Star Scientific, Inc. (Nasdaq:STSI) from May 14, 2012, to January 22, 2013,
seeking remedies under the federal securities laws.

To join the Star Scientific, visit the firm's website at
http://rosenlegal.com, or call Phillip Kim, Esq. or Jonathan Horne, Esq.
toll-free, at 866-767-3653; you may also email pkim@rosenlegal.com or
jhorne@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS
CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY
CHOOSE TO DO NOTHING AT THIS POINT AND REMAIN AN ABSENT CLASS MEMBER.

Throughout 2012, STSI touted its relationship with Johns Hopkins University,
who STSI claimed was purportedly conducting studies relating to STSI's
product, Anatabloc. For example, a press release dated June 27, 2012 stated
that research had been conducted by "[t]he independently funded research team
at Johns Hopkins [....]" In a Press Release dated January 7, 2013 announcing
the results of STSI's clinical trials, STSI quoted Dr. Paul Ladenson of Johns
Hopkins University, but omitted mention of Johns Hopkins University.

On January 23, 2013, TheStreet.com published an article refuting claims that
John's Hopkins was conducting clinical trials with STSI. In the article, a
Johns Hopkins spokesperson is quoted as responding to Star Scientific's claim
that it was conducting a study with Johns Hopkins by stating: "We do have
guidelines about such things and he [Ladenson] is in violation here." The
Johns Hopkins spokesperson purportedly added that Johns Hopkins had started an
inquiry into the conduct. As a result of this adverse news, the price of STSI
stock fell on January 23, 2013, damaging investors. On March 18, 2013, Star
Scientific filed its 10-K for 2012, in which it announced that it and its
personnel had received subpoenas from the U.S. Attorney's Office.

If you wish to serve as lead plaintiff, you must move the Court no later than
May 24, 2013. A lead plaintiff is a representative party acting on behalf of
other class members in directing the litigation. If you wish to join the
litigation, or to discuss your rights or interests regarding this class
action, please contact Jonathan Horne, Esq. of The Rosen Law Firm, toll-free,
at 866-767-3653, or via e-mail at jhorne@rosenlegal.com. You may also visit
the firm's website at http://www.rosenlegal.com.

The Rosen Law Firm represents investors throughout the globe, concentrating
its practice in securities class actions and shareholder derivative
litigation.

CONTACT: Laurence Rosen, Esq.
         Phillip Kim, Esq.
         The Rosen Law Firm P.A.
         275 Madison Avenue, 34th Floor
         New York, New York 10016
         Tel:  (212) 686-1060
         Toll Free: 1-866-767-3653
         Fax: (212) 202-3827
         lrosen@rosenlegal.com
         pkim@rosenlegal.com
         www.rosenlegal.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement